Servier's $2.5bn Acquisition of Day One Biopharmaceuticals
- Apr 29
- 5 min read
By Rakan Aqrouq, Krissa Mou, Scarlet Park, and Terry Zhang (University of British Columbia); Amin Ouamar, Gilles Michaud, and Marc Bellon (HEC Paris).
Photo: Piron Guillame
Overview of the deal
Acquirer: Laboratoires Servier
Target: Day One Biopharmaceuticals
Implied Equity Value: $2.5 bn
Total Transaction Size: $2.5 bn
Closed date: Announced on March 6th, 2026. Expected to close in Q2 2026
Target advisor: Centerview Partners, (financial), Fenwick & West, Wilson Sonsini Goodrich & Rosati (legal)
Acquirer advisor: Goldman Sachs Bank Europe (financial), Baker McKenzie (legal)
The proposed acquisition of Day One Biopharmaceuticals by Servier reflects a strategic effort to expand Servier’s oncology platform, especially in rare and pediatric cancers. Day One brings Ojemda, the only FDA-approved monotherapy for pediatric low-grade glioma, along with a broader pipeline ranging from early-stage programs to Phase III. By acquiring Day One for $21.50 per share in cash, valuing the company at roughly $2.5 billion, Servier can become bigger in a focused therapeutic area and deepen its position in targeted oncology under its broader 2030 growth strategy.
The transaction also helps pre-empt competition by securing a differentiated asset before rivals can build a similar position in pediatric brain tumors. In biotech, approved therapies and strong development pipelines are hard to find, and the teams behind them are equally difficult to replicate. By acquiring Day One, Servier not only gains a differentiated asset base but also strengthens its long-term position in oncology. The value of the deal comes less from traditional manufacturing scale and more from Servier’s ability to advance and commercialize Day One’s portfolio using its existing development, regulatory, and market access capabilities. That should improve the speed and reach of future oncology programs while supporting innovation in high-unmet-need cancers.
“The acquisition of Day One Biopharmaceuticals marks another decisive step in strengthening Servier’s position in rare oncology.” - Olivier Laureau, Head of Servier
Company Details (Acquirer - Servier)
Servier is an independent, international pharmaceutical company that focuses on therapeutic progress in several areas of medicine, with patients having a voice during the entire process. Servier leverages its patients taking an active role to meet the specific needs of each patient, from the rarest to the most common diseases. Their three key areas are cancer, cardiometabolism, and neurology. Servier aims by 2030 to have 100% of its clinical trial protocols and solutions be developed with patients. The company has a unique governance model, being governed by a foundation, in order to ensure that the company is fully invested in meeting patient needs.
Founded in 1954, headquartered in Suresnes, France
CEO: Olivier Laureau
Number of employees: 20,000+
Market Cap: N/A (Private)
EV: N/A
LTM Revenue: €6.86bn
LTM EBITDA: €1.93bn
LTM EV/Revenue: N/A
LTM EV/EBITDA: N/A
Recent Transactions: $2 billion acquisition of Agios Pharmaceuticals' oncology business (Dec 2020)
Company Details (Target - Day One Biopharmaceuticals)
Day One Biopharmaceuticals is a U.S.-based biopharmaceutical company focused on developing targeted therapies for patients with cancer, with a strong emphasis on pediatric oncology. The company aims to address unmet medical needs by combining precision medicine with a patient-focused approach. Its strategy is to develop drugs that can be used across age groups but with a particular focus on childhood cancers. Even though the company is still young and not yet profitable, it received its first FDA approval for one of its medicines in 2024.
Founded in 2018, headquartered in Brisbane, California, United States.
CEO: Jeremy Bender
Number of employees: ~180
Market Cap: ~$2.2 billion (as of early April 2026)
EV: ~$1.9 billion
LTM Revenue: ~$155 million (FY 2025)
LTM EBITDA: Negative
LTM EV/Revenue: ≈12.6x
LTM EV/EBITDA: Not meaningful (negative EBITDA)
Projections and Assumptions
Short-Term Consequences
In the near term, Servier’s all-cash bid for Day One at 21.50 USD per share, or 68% above undisturbed levels and 86% above the 1-month VWAP, effectively redefines DAWN as a high-beta, money-losing biotech issuer, now being used as a tool for merger arbitrage. The returns profile of DAWN in the next 6-12 months is driven by a small spread rather than any binary events. Fundamental capital is largely exited at an attractive cash return, with event-driven capital set to profit from the spread with an expected close in 2Q 2026.
From Servier’s perspective, the immediate impact is that they give up liquidity on their balance sheet in return for a small but fast-growing rare oncology business (Ojemda, with 2025E sales of approximately 155 million USD) with an operating loss profile, indicating growing top-line revenue with EPS pressure until integration synergies and Ojemda growth opportunities start to materialize. From a strategic perspective, Servier is strengthening its presence in pediatric low-grade glioma and rare oncology, with the deal also indicating that well-capitalized pharmaceutical companies remain active in pursuing de-risked, small oncology platforms in the 2-3 billion USD range. Over the next year, this dynamic is likely further to cement valuation anchors and M&A optionality in small-cap oncology.
Long-Term Upsides
The acquisition of Day One Biopharmaceuticals marks a strategic acceleration of Servier's ambition to become a global leader in rare oncology. Following the acquisitions of Shire's oncology business in 2018 and Agios Pharmaceuticals' cancer portfolio in 2021 — which delivered the approved therapies Tibsovo and Voranigo — the integration of Day One deepens Servier's expertise in brain tumors and broadens its commercial reach in the United States.
The centerpiece of the deal is Ojemda, a once-weekly oral treatment approved by the FDA in April 2024 for pediatric low-grade glioma, the most common form of childhood brain cancer. Ojemda holds a key competitive edge over Novartis' rival therapy: it treats a broader range of genetic profiles, covering roughly 80% of affected patients versus a narrower subset for Novartis. Commercially, the drug generated $155.4 million in revenue in 2025, up 172% year-over-year, with guidance of $225–250 million for 2026, directly fueling Servier's target of €4 billion in oncology sales by 2030.
Beyond this, Day One is running a late-stage trial to evaluate Ojemda as a first-line therapy, which would allow it to be prescribed before chemotherapy. If successful, results expected by mid-2027 could lead to approval by 2028, substantially enlarging the drug's market. The deal also brings two earlier-stage candidates targeting other rare cancers, plus an existing licensing agreement with Ipsen for global commercialization, positioning Servier to build a diversified oncology platform on its path toward €10 billion in total revenue by 2030.
Risks and Uncertainties
The most significant risk lies in Ojemda's regulatory status. The drug was approved through an accelerated pathway, a process the FDA uses to grant early access to promising treatments before long-term benefit has been fully demonstrated. Continued approval depends on an ongoing confirmatory trial proving that Ojemda outperforms standard chemotherapy. Should this trial fail, the FDA could withdraw the approval, undermining the commercial foundation on which the $2.5 billion valuation rests.
In parallel, the market for pediatric low-grade glioma, while underserved, remains inherently small, approximately 13,000 patients across 212 U.S. treatment centers. This places a natural ceiling on revenue. Sustained growth depends on pricing power and patient persistency, both of which could be challenged by insurer pushback or new competing therapies from players such as Novartis.
The earlier-stage pipeline assets also carry meaningful risk. Both inherited drug candidates remain in Phase 1, the earliest stage of human testing — with results not expected until mid-to-late 2026. Given the historically high attrition rates in oncology, their commercial viability is far from assured.
Finally, Servier's structure as a privately held, foundation-governed group limits its access to capital markets. With cumulative oncology M&A spending approaching $7 billion since 2018, the group's financial flexibility for future transformative deals may be narrowing at a time when competition in rare oncology is intensifying.